Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director David R. Epstein sold 620 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the sale, the director now directly owns 27,894 shares of the company's stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
NASDAQ TEM traded down $0.99 during trading on Friday, hitting $41.00. The stock had a trading volume of 5,041,241 shares, compared to its average volume of 1,427,998. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The firm's 50 day moving average price is $52.88. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.
A number of analysts have issued reports on the stock. Wolfe Research assumed coverage on shares of Tempus AI in a report on Friday. They issued an "outperform" rating and a $60.00 price target on the stock. Loop Capital increased their target price on Tempus AI from $48.00 to $57.00 and gave the company a "buy" rating in a research report on Tuesday, October 15th. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research report on Friday. Piper Sandler reiterated a "neutral" rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Stifel Nicolaus cut shares of Tempus AI from a "buy" rating to a "hold" rating and upped their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, Tempus AI presently has an average rating of "Moderate Buy" and an average price target of $56.00.
Read Our Latest Stock Report on Tempus AI
A number of institutional investors and hedge funds have recently modified their holdings of the business. EFG Asset Management North America Corp. purchased a new stake in Tempus AI in the second quarter worth $1,333,000. ARK Investment Management LLC bought a new position in shares of Tempus AI in the second quarter worth about $18,294,000. Northwestern University purchased a new position in Tempus AI in the 2nd quarter worth about $491,000. Alphabet Inc. purchased a new stake in Tempus AI in the 2nd quarter valued at about $54,289,000. Finally, Pier Capital LLC bought a new position in Tempus AI in the 2nd quarter worth about $2,301,000. 24.22% of the stock is owned by institutional investors.
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.